The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Paul Ehrlich's magic bullet concept: 100 years of progress
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 270
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Towards a proteome-scale map of the human protein–protein interaction network
Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., et al. (2005) · Nature · doi:10.1038/nature04209 · Cited by 2,933
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Møller, N. P. H., Risau, W., & Ullrich, A. (1993) · Cell · doi:10.1016/0092-8674(93)90573-9 · Cited by 1,927
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citationFarber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Ludwig, J. A., & Weinstein, J. N. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1739 · Cited by 1,666
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Self-citationCardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Computer-based de novo design of drug-like molecules
Schneider, G., & Fechner, U. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1799 · Cited by 948
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
Self-citationImproving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Self-citationBartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747
The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides
Gilman, A., & Philips, F. S. (1946) · Science · doi:10.1126/science.103.2675.409 · Cited by 732
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564
Cancer revoked: oncogenes as therapeutic targets
Felsher, D. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1070 · Cited by 556
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040546297 · Cited by 477
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Croonian lecture.—On immunity with special reference to cell life
Ehrlich, P. (1900) · Proceedings of the Royal Society of London · doi:10.1098/rspl.1899.0121 · Cited by 441
ADMET—turning chemicals into drugs
Hodgson, J. (2001) · Nature Biotechnology · doi:10.1038/90761 · Cited by 423
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
Thomas, R. K., Nickerson, E., Simons, J. F., Jänne, P. A., Tengs, T., Yuza, Y., Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1437 · Cited by 361
Über den jetzigen Stand der Chemotherapie
Ehrlich, P. (1909) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.19090420105 · Cited by 348
The initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
A probability-based approach for the analysis of large-scale RNAi screens
König, R., Chiang, C.-Y., Tu, B. P., Yan, S. F., DeJesus, P. D., Romero, A., Bergauer, T., Orth, A., Krueger, U., Zhou, Y., et al. (2007) · Nature Methods · doi:10.1038/nmeth1089 · Cited by 338
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535024100 · Cited by 336
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Self-citationSpankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 327
Self-citationThe clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Rowinsky, E. K., & Donehower, R. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90086-2 · Cited by 321
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., & Kuriyan, J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040144 · Cited by 309
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Holtrich, U., Wolf, G., Bräuninger, A., Karn, T., Böhme, B., Rübsamen-Waigmann, H., & Strebhardt, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1736 · Cited by 275
Self-citationByrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264
Comprehensive Survey of Combinatorial Library Synthesis: 2000
Dolle, R. E. (2001) · Journal of Combinatorial Chemistry · doi:10.1021/cc010049g · Cited by 256
Prewett, M., Scher, H. I., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., & Goldstein, N. I. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199611000-00006 · Cited by 244
Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies
Becher, O. J., & Holland, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3827 · Cited by 243
Comparative QSAR: Toward a Deeper Understanding of Chemicobiological Interactions
Hansch, C., Hoekman, D., & Gao, H. (1996) · Chemical Reviews · doi:10.1021/cr9400976 · Cited by 236
Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions
Reindl, W., Yuan, J., Krämer, A., Strebhardt, K., & Berg, T. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.013 · Cited by 232
Self-citationChatal, J.-F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J.-P., Charbonnel, B., Rohmer, V., Chang, C.-H., Sharkey, R. M., Goldenberg, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4917 · Cited by 232
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
van Mierlo, G. J. D., den Boer, A. T., Medema, J. P., van der Voort, E. I. H., Fransen, M. F., Offringa, R., Melief, C. J. M., & Toes, R. E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082107699 · Cited by 222
Crooke, S. T., & Bradner, W. T. (1976) · PubMed · Cited by 213
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Solit, D. B., Ivy, S. P., Kopil, C., Sikorski, R., Morris, M. J., Slovin, S. F., Kelly, W. K., DeLaCruz, A., Curley, T., Heller, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1863 · Cited by 211
Monoclonal Antibody Therapy for Cancer
Mehren, M. V., Adams, G. P., & Weiner, L. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152442 · Cited by 191
Cortes, E. P. (1972) · JAMA · doi:10.1001/jama.1972.03200230020005 · Cited by 183
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603851 · Cited by 183
A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia
FREI, E., HOLLAND, J. F., SCHNEIDERMAN, M. A., PINKEL, D., SELKIRK, G., FREIREICH, E. J., SILVER, R. T., GOLD, G. L., & REGELSON, W. (1958) · Blood · doi:10.1182/blood.v13.12.1126.1126 · Cited by 179
Comprehensive Survey of Combinatorial Library Synthesis: 1999
Dolle, R. E. (2000) · Journal of Combinatorial Chemistry · doi:10.1021/cc000055x · Cited by 164
Preclinical and Clinical Pharmacology of Vinca Alkaloids
Zhou, X.-J., & Rahmani, R. (1992) · Drugs · doi:10.2165/00003495-199200444-00002 · Cited by 163
Da, F., & Rk, J. (1978) · PubMed · Cited by 162
Galizia, G., Lieto, E., De Vita, F., Orditura, M., Castellano, P., Troiani, T., Imperatore, V, & Ciardiello, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210381 · Cited by 161
Localization of the colchicine-binding site of tubulin.
Uppuluri, S., Knipling, L., Sackett, D. L., & Wolff, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11598 · Cited by 157
Issell, B. F., & Crooke, S. T. (1978) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(78)80014-0 · Cited by 152
Substrate Competitive Inhibitors of IGF-1 Receptor Kinase
Blum, G., Gazit, A., & Levitzki, A. (2000) · Biochemistry · doi:10.1021/bi001516y · Cited by 151
Sharp, S. Y., Prodromou, C., Boxall, K. J., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K.-M. J., Kalusa, A., James, K. E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0149 · Cited by 145
Targeting Cell Cycle Kinases for Cancer Therapy
de Cárcer, G., de Castro, I. P., & Malumbres, M. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780362925 · Cited by 144
Doxorubicin in disseminated osteosarcoma
Cores, E. P. (1972) · JAMA · doi:10.1001/jama.221.10.1132 · Cited by 138
THE CHEMISTRY AND BIOCHEMISTRY OF PURINE ANALOGS
Hitchings, G. H., & Elion, G. B. (1954) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1954.tb40008.x · Cited by 136
Clinical and biological significance of HSP89 alpha in human breast cancer
Jameel, A., Skilton, R. A., Campbell, T., Chander, S. K., Coombes, R. C., & Luqmani, Y. A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500315 · Cited by 119
Expression and Roles of Heat Shock Proteins in Human Breast Cancer
Yano, M., Naito, Z., Tanaka, S., & Asano, G. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb02119.x · Cited by 116
Chaudry, M. A., Sales, K. M., Ruf, P., Lindhofer, H., & Winslet, M. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603505 · Cited by 97
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Karagiannis, T. C., & El‐Osta, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404464 · Cited by 96
Bagatell, R., Gore, L., Egorin, M. J., Ho, R. H., Heller, G., Boucher, N., Zuhowski, E. G., Whitlock, J. A., Hunger, S. P., Narendran, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1892 · Cited by 95
Ramanathan, R. K., Egorin, M. J., Eiseman, J. L., Ramalingam, S. S., Friedland, D., Agarwala, S. S., Ivy, S. P., Potter, D. M., Chatta, G. S., Zuhowski, E. G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2233 · Cited by 87
Harsh, S., Adhikari, A., Parazuli, P., Pathak, R., Khadga, P. K., & Sharma, S. (2015) · Journal of Advances in Internal Medicine · doi:10.3126/jaim.v4i1.14173 · Cited by 78
Zimmermann, J., Caravatti, G., Mett, H., Meyer, T., Müller, M., Lydon, N., & Fabbro, D. (1996) · Archiv der Pharmazie · doi:10.1002/ardp.19963290707 · Cited by 77
Novel radiolabeled antibody conjugates
Goldenberg, D. M., & Sharkey, R. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210373 · Cited by 64
Fleming, A., Voureka, A., Kramer, I. R. H., & Hughes, W. H. (1950) · Journal of General Microbiology · doi:10.1099/00221287-4-2-257 · Cited by 62
Herceptin-Geldanamycin Immunoconjugates
Mandler, R., Kobayashi, H., Hinson, E. R., Brechbiel, M. W., & Waldmann, T. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2485 · Cited by 60
Wang, J., & Ramnarayan, K. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc990032m · Cited by 55
Chemotherapeutische Trypanosomen-Studien
Ehrlich, P. F. (1960) · Elsevier eBooks · doi:10.1016/b978-0-08-009056-6.50014-2 · Cited by 49
Identification of a Small-Molecule Inhibitor of Class Ia PI3Ks with Cell-Based Screening
Yang, J., Shamji, A. F., Matchacheep, S., & Schreiber, S. L. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.02.004 · Cited by 47
Protein crystallization: virtual screening and optimization
DeLucas, L. J., Hamrick, D., Cosenza, L., Nagy, L. A., McCombs, D., Bray, T. L., Chait, A., Stoops, B., Belgovskiy, A., Wilson, W. W., et al. (2004) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2004.07.008 · Cited by 44
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors
Sarver, R. W., Peevers, J., Cody, W. L., et al. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.10.017 · Cited by 44
Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors
Khawli, L. A., Hu, P., & Epstein, A. L. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_13 · Cited by 33
Designing Immunotoxins for Cancer Therapy
Pennell, C. A., & Erickson, H. A. (2002) · Immunologic Research · doi:10.1385/ir:25:2:177 · Cited by 33
Tumor inhibition by genomically integrated inducible RNAi-cassettes
Kappel, S., Matthess, Y., Zimmer, B., Kaufmann, M., & Strebhardt, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl628 · Cited by 32
Self-citationAus Theorie und Praxis der Chemotherapie
EHRLICH, P., & WALDEYER, W. (1960) · Elsevier eBooks · doi:10.1016/b978-0-08-009056-6.50036-1 · Cited by 28
Screening and evaluation of anticancer agents.
Zee-Cheng, R. K. Y., & Cheng, C. C. (1988) · PubMed · Cited by 14
Expanding the repertoire of RNA interference screens for developing new anticancer drug targets
Haney, S. A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.11.1429 · Cited by 13
Cited by
Mesoporous silica nanoparticles in biomedical applications
Li, Z., Barnes, J. C., Bosoy, A., Stoddart, J. F., & Zink, J. I. (2012) · Chemical Society Reviews · doi:10.1039/c1cs15246g · Cited by 1,907
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Insight into nanoparticle cellular uptake and intracellular targeting
Yameen, B., Choi, W. I., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.038 · Cited by 787
Metadata
- Authors
- Strebhardt, K., & Ullrich, A.
- Venue
- Nature Reviews Cancer
- Published
- 2008-05-12
- Volume
- 8
- Issue
- 6
- Pages
- 473-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2018478612
- Cited by
- 1,457
- References
- 138
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.